Significance of baseline quality of life scores in predicting clinical outcomes in an international phase III trial of advanced pancreatic cancer: NCIC CTG PA.3.

摘要: 4053 Background: There is insufficient information regarding the prognostic significance of baseline Quality life (QoL) scores on overall survival (OS) and adverse events (AEs) in advanced pancreatic cancer. Methods: QoL was assessed prospectively using EORTC QLQ-C30 AEs were graded NCI Common Toxicity Criteria version 2.0 as part PA.3 trial gemcitabine + erlotinib (G+E) vs. placebo (G+P). Relevant clinical variables, ECOG performance status (PS), at analyzed by Cox stepwise regression to determine predictors OS AEs. transformed square root. Results: 222 285 patients (pts) (78%) treated with G+E 220 284 pts (77%) G+P completed assessments. In a multivariate analysis (MVA) combining all pts, better physical function (PF) score independently incrementally predicted longer (HR 0.91; CI: 0.83-1.00), did non-white race 0.62; 0.42-0.91), PS 0-1 (vs. PS...